Latest dyslipidemia Stories
Submission of Application in Japan Marks an Important Milestone in Strategic Partnership With Amgen Astellas BioPharma THOUSAND OAKS, Calif., March 20, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN)
Data From PCSK9 Inhibitor Study Support Regulatory Filing in Japan THOUSAND OAKS, Calif., March 14, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase
The 19th Annual CME Conference on Hypertension, Diabetes and Dyslipidemia is scheduled for June 26-28 in Charleston, SC by the Continuing Education Company Inc.
The agenda for the 19th Annual Conference on Hypertension, Diabetes and Dyslipidemia has been released.
RnRMarketResearch.com adds “Dyslipidemia – Pipeline Review, H1 2015” to its store.
Additional Data Analysis Showed Every Two Week and Monthly Dosing Regimens of Evolocumab Were Clinically Equivalent THOUSAND OAKS, Calif., Nov.
THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.
DALLAS, October 21, 2014 /PRNewswire/ -- RnRMarketResearch.com adds EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023 market research of 94 pages to the Therapeutics
Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia
Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Aug.
- An armed gangster.